S&P 500   4,990.97 (+0.48%)
DOW   38,125.64 (+0.37%)
QQQ   416.15 (+0.36%)
AAPL   165.52 (+0.32%)
MSFT   398.65 (-0.12%)
META   478.57 (-0.52%)
GOOGL   155.53 (+0.93%)
AMZN   175.35 (+0.41%)
TSLA   141.30 (-3.91%)
NVDA   783.51 (+2.82%)
AMD   147.04 (+0.27%)
NIO   3.89 (+2.37%)
BABA   70.19 (+1.62%)
T   16.24 (-1.64%)
F   12.69 (+4.53%)
MU   107.98 (+1.13%)
GE   149.60 (+1.04%)
CGC   7.73 (-2.52%)
DIS   112.12 (-0.44%)
AMC   3.42 (+8.23%)
PFE   26.27 (+1.04%)
PYPL   62.76 (+0.72%)
XOM   120.61 (+0.61%)
S&P 500   4,990.97 (+0.48%)
DOW   38,125.64 (+0.37%)
QQQ   416.15 (+0.36%)
AAPL   165.52 (+0.32%)
MSFT   398.65 (-0.12%)
META   478.57 (-0.52%)
GOOGL   155.53 (+0.93%)
AMZN   175.35 (+0.41%)
TSLA   141.30 (-3.91%)
NVDA   783.51 (+2.82%)
AMD   147.04 (+0.27%)
NIO   3.89 (+2.37%)
BABA   70.19 (+1.62%)
T   16.24 (-1.64%)
F   12.69 (+4.53%)
MU   107.98 (+1.13%)
GE   149.60 (+1.04%)
CGC   7.73 (-2.52%)
DIS   112.12 (-0.44%)
AMC   3.42 (+8.23%)
PFE   26.27 (+1.04%)
PYPL   62.76 (+0.72%)
XOM   120.61 (+0.61%)
S&P 500   4,990.97 (+0.48%)
DOW   38,125.64 (+0.37%)
QQQ   416.15 (+0.36%)
AAPL   165.52 (+0.32%)
MSFT   398.65 (-0.12%)
META   478.57 (-0.52%)
GOOGL   155.53 (+0.93%)
AMZN   175.35 (+0.41%)
TSLA   141.30 (-3.91%)
NVDA   783.51 (+2.82%)
AMD   147.04 (+0.27%)
NIO   3.89 (+2.37%)
BABA   70.19 (+1.62%)
T   16.24 (-1.64%)
F   12.69 (+4.53%)
MU   107.98 (+1.13%)
GE   149.60 (+1.04%)
CGC   7.73 (-2.52%)
DIS   112.12 (-0.44%)
AMC   3.42 (+8.23%)
PFE   26.27 (+1.04%)
PYPL   62.76 (+0.72%)
XOM   120.61 (+0.61%)
S&P 500   4,990.97 (+0.48%)
DOW   38,125.64 (+0.37%)
QQQ   416.15 (+0.36%)
AAPL   165.52 (+0.32%)
MSFT   398.65 (-0.12%)
META   478.57 (-0.52%)
GOOGL   155.53 (+0.93%)
AMZN   175.35 (+0.41%)
TSLA   141.30 (-3.91%)
NVDA   783.51 (+2.82%)
AMD   147.04 (+0.27%)
NIO   3.89 (+2.37%)
BABA   70.19 (+1.62%)
T   16.24 (-1.64%)
F   12.69 (+4.53%)
MU   107.98 (+1.13%)
GE   149.60 (+1.04%)
CGC   7.73 (-2.52%)
DIS   112.12 (-0.44%)
AMC   3.42 (+8.23%)
PFE   26.27 (+1.04%)
PYPL   62.76 (+0.72%)
XOM   120.61 (+0.61%)
NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Price, News & Analysis

$5.34
0.00 (0.00%)
(As of 11:57 AM ET)
Today's Range
$5.34
$6.00
50-Day Range
$3.87
$10.65
52-Week Range
$2.38
$11.99
Volume
124,741 shs
Average Volume
257,816 shs
Market Capitalization
$57.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Lantern Pharma MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Lantern Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$360,340 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.02) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.02 out of 5 stars

Medical Sector

904th out of 907 stocks

Pharmaceutical Preparations Industry

426th out of 428 stocks

LTRN stock logo

About Lantern Pharma Stock (NASDAQ:LTRN)

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN Stock Price History

LTRN Stock News Headlines

Lantern Pharma Inc. (LTRN)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Lantern Pharma Inc Ordinary Shares
Lantern Pharma Inc (LTRN)
LTRN: 2023 Results
H.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Recap: Lantern Pharma Q4 Earnings
LTRN May 2024 5.000 call
LTRN Apr 2024 12.500 call
Lantern Pharma Earnings Preview
LTRN Mar 2024 10.000 call
LTRN Oct 2024 5.000 put
LTRN Apr 2024 2.500 call
LTRN Mar 2024 7.500 call
See More Headlines
Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/22/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LTRN
Fax
N/A
Employees
21
Year Founded
2013

Profitability

Net Income
$-15,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.76 per share

Miscellaneous

Free Float
9,998,000
Market Cap
$57.35 million
Optionable
Optionable
Beta
1.40

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Panna Sharma PH.D. (Age 53)
    President, CEO & Director
    Comp: $633.25k
  • Mr. David R. Margrave (Age 63)
    CFO & Secretary
    Comp: $394.36k
  • Dr. Kishor Gopaldas Bhatia Ph.D. (Age 69)
    Chief Scientific Officer & Scientific Consultant
    Comp: $184.33k
  • Nicole Leber
    Investor Relations Associate, Finance & Administrative Coordinator
  • Dr. Peter L. Nara D.V.M.
    M.S., Ph.D., Co-Founder & Advisor
  • Mr. Ernest Kitt B.S.
    M.S, Head of Clinical Operations

LTRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantern Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LTRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LTRN, but not buy additional shares or sell existing shares.
View LTRN analyst ratings
or view top-rated stocks.

How have LTRN shares performed in 2024?

Lantern Pharma's stock was trading at $4.28 at the beginning of 2024. Since then, LTRN shares have increased by 24.8% and is now trading at $5.34.
View the best growth stocks for 2024 here
.

Are investors shorting Lantern Pharma?

Lantern Pharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 420,900 shares, an increase of 191.1% from the March 15th total of 144,600 shares. Based on an average trading volume of 276,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 5.3% of the company's shares are short sold.
View Lantern Pharma's Short Interest
.

When is Lantern Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LTRN earnings forecast
.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) announced its earnings results on Monday, March, 18th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01.

What ETF holds Lantern Pharma's stock?

Horizon Kinetics Medical ETF holds 28,791 shares of LTRN stock, representing 1.31% of its portfolio.

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK).

When did Lantern Pharma IPO?

Lantern Pharma (LTRN) raised $26 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Who are Lantern Pharma's major shareholders?

Lantern Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pathway Financial Advisors LLC (0.23%). Insiders that own company stock include Aaron GL Fletcher and Leslie W Kreis.
View institutional ownership trends
.

How do I buy shares of Lantern Pharma?

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LTRN) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners